CoVaccine HT™ |
|
Vaxjo ID |
238 |
|
Vaccine Adjuvant Name |
CoVaccine HT™ |
|
Alternative Names |
SFASE-based adjuvant (Sucrose Fatty Acid Sulfate Ester) |
|
Adjuvant VO ID |
VO_0005575
|
|
Description |
An oil-in-water nanoemulsion adjuvant with squalane droplets coated with sucrose fatty acid sulfate ester (SFASE), designed to enhance both humoral and cellular immunity |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
CoVaccine HT™adjuvant, an oil-in-water nanoemulsion compatible with lyophilization |
|
Structure |
Submicrometer-sized squalane droplets stabilized by sucrose fatty acid sulfate esters in water |
|
Appearance |
Liquid nanoemulsion, suitable for lyophilization (freeze-drying) |
|
Storage |
Stable up to 12 weeks at 40°C; compatible with long-term ambient storage when lyophilized |
|
Preparation |
Mixed with recombinant proteins such as SdTM/SdTM2P (stabilized SARS-CoV-2 spike) prior to intramuscular injection |
|
Dosage |
Typically 1 mg of CoVaccine HT™ with 5 µg of antigen per dose; lower doses (e.g., 0.3 mg) also effective |
|
Function |
We demonstrated that, when formulated with CoVaccine HT™adjuvant, an oil-in-water nanoemulsion compatible with lyophilization, our vaccine candidates elicit a broad-spectrum IgG response, high neutralizing antibody titers, and a robust, antigen-specific IFN-γ secreting response from immune splenocytes in outbred mice |
|
Safety |
Demonstrated a favorable safety profile in mice; no signs of enhanced disease or eosinophilic inflammation |
| References |
Lai et al., 2021: Lai CY, To A, Wong TAS, Lieberman MM, Clements DE, Senda JT, Ball AH, Pessaint L, Andersen H, Donini O, Lehrer AT. Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice. bioRxiv : the preprint server for biology. 2021; ; . [PubMed: 33688645].
|
